Focal adhesion kinase (FAK) is a 125-kDa non-receptor type
tyrosine kinase that localizes to focal adhesions. FAK overexpression is frequently found in invasive and metastatic
cancers of the breast, colon, thyroid, and prostate, but its role in osteolytic
metastasis is not well understood. In this study, we have analyzed anti-
tumor effects of the novel FAK Tyr(397) inhibitor
TAE226 against bone
metastasis in
breast cancer by using
TAE226.
Oral administration of
TAE226 in mice significantly decreased bone
metastasis and osteoclasts involved which were induced by MDA-MB-231
breast cancer cells and increased the survival rate of the mouse models of bone
metastasis.
TAE226 also suppressed the growth of subcutaneous
tumors in vivo and the proliferation and migration of MDA-MB-231 cells in vitro. Significantly,
TAE226 inhibited the osteoclast formation in murine pre-osteoclastic RAW264.7 cells, and actin ring and pit formation in mature osteoclasts. Moreover,
TAE226 inhibited the receptor activator for nuclear factor κ B
Ligand (RANKL) gene expression induced by
parathyroid hormone-related protein (
PTHrP) in bone stromal ST2 cells and blood free
calcium concentration induced by
PTHrP administration in vivo. These findings suggest that FAK was critically involved in osteolytic
metastasis and activated in
tumors, pre-osteoclasts, mature osteoclasts, and bone stromal cells and
TAE226 can be effectively used for the treatment of
cancer induced bone
metastasis and other
bone diseases.